Ganirelix
Anti-Gonadotropin-Releasing Hormones
Sold as Orgalutran
- Drug class
- Anti-Gonadotropin-Releasing Hormones
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 6
Overview
Ganirelix is an active pharmaceutical ingredient in the Anti-Gonadotropin-Releasing Hormones group (H01CC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 3 | April 17, 2026 |
| EU European Union | EMA | 2 | December 18, 2025 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
3 products
Uses
Ganirelix Gedeon Richter is indicated for the prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART). In clinical studies ganirelix was used with recombinant human follicle stimulating hormone (FSH) or corifollitropin alfa, the sustained follicle stimulant.
How to take
EUEuropean Union· EMA
2 products
Uses
Orgalutran is indicated for the prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART). In clinical studies Orgalutran was used with recombinant human follicle stimulating hormone (FSH) or corifollitropin alfa, the sustained follicle stimulant.
How to take
CACanada· Health Canada
1 product
Uses
ORGALUTRAN® (ganirelix injection) is indicated for the prevention of premature LH surges in women undergoing controlled ovarian hyperstimulation (COH). 1 Pediatrics Pediatrics (< 18 years of age): ORGALUTRAN® (ganirelix injection) is not indicated for pediatric use.
Based on the data submitted and reviewed by Health Canada, the safety and efficacy of ORGALUTRAN®, in pediatric patients has not been established. 2 Geriatrics Geriatrics: ORGALUTRAN® (ganirelix injection) is not indicated for geriatric use.
No data are available to Health Canada.
How to take
Drug interactions
Known interactions involving Ganirelix. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB048540193 · revised April 17, 2026
- [2]European Medicines Agency · EMEA/H/C/000274 · revised December 18, 2025
- [3]Health Canada (DPD) · 02245641 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.